Here's your US drug review news for week in brief: The Food and Drug Administration issued one long-awaited approval – for Pfizer Inc.’s tafamidis products Vyndaqel and Vyndamax – and one under-the-radar application, for Ruzurgi, an amifampridine product from Jacobus Pharmaceutical Company. Acacia Pharma Ltd. was not so lucky, receiving a second complete response letter for the anti-emetic Barhemsys.
Submissions clustered around new formulations and combinations, thanks to RedHill Biopharma Ltd.’s three-drug combo for Helicobacter pylori infection,








